Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.
Charles A PeloquinPatrick P J PhillipsCarole D MitnickKathleen EisenachRamonde F PatientiaLeonid LeccaEduardo GotuzzoNeel R GandhiDonna ButlerAndreas H DiaconBruno MartelJuan SantillanKathleen Robergeau HuntDante VargasFlorian von Groote-BidlingmaierCarlos SeasNancy DianisAntonio Moreno-MartinezPawandeep KaurC Robert HorsburghPublished in: Antimicrobial agents and chemotherapy (2018)
Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.).
Keyphrases
- multidrug resistant
- south africa
- end stage renal disease
- mycobacterium tuberculosis
- air pollution
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- open label
- pulmonary tuberculosis
- adverse drug
- double blind
- drug resistant
- hiv positive
- placebo controlled
- cystic fibrosis
- patient reported outcomes
- combination therapy
- smoking cessation
- human immunodeficiency virus
- hiv infected
- body weight